4 results
This research has the goal to determine which treatment is the most effective treatment in terms of prevention of treatment failure, in costs and has the patients preference when comparing PDT, Imiquimod and 5FU.
To assess the efficacy of the co-administration of lanreotide Autogel 120 mg(administered via deep sub-cutaneous injections every 28 days) and pegvisomant(administered at 40 to 120 mg per week via sub-cutaneous injection given once ortwice a week)…
Primary: To evaluate the efficacy of tisagenlecleucel therapy as measured by overall response rate by investigator assessment.Secondary: Duration of response, event free survival, relapse free survival, overall survival, safety, kinetics,…
To compare tisagenlecleucel treatment strategy to SOC treatment strategy with respect to delaying the composite event of disease progression / stable disease at or after the week 12 assessment; or death at any time.